Introduction:

Alpesib 150 mg, manufactured by Everest Pharmaceuticals Ltd and supplied by Orio Pharma, is a targeted therapy used in the treatment of advanced breast cancer. Containing Alpelisib, Alpesib 150 mg is a PI3K inhibitor designed to treat hormone receptor-positive, HER2-negative breast cancer in patients who have a PIK3CA gene mutation. This therapy plays a crucial role in controlling cancer progression, particularly in cases where the disease has become resistant to hormonal therapy.

Manufacturing Excellence of Everest Pharmaceuticals Ltd.:

Everest Pharmaceuticals Ltd. is dedicated to producing innovative and high-quality pharmaceutical products that meet stringent global standards. The development of Alpesib 150 mg reflects their commitment to advancing cancer treatment through rigorous research, excellent quality control, and best manufacturing practices. Their focus on safety and efficacy ensures that Alpesib 150 mg is a reliable option for managing advanced breast cancer.

Mechanism of Action:

Alpesib 150 mg contains Alpelisib, a PI3K (phosphatidylinositol 3-kinase) inhibitor that works by selectively inhibiting the alpha isoform of the enzyme in cancer cells. The PI3K pathway is often overactive in breast cancer due to mutations in the PIK3CA gene, leading to uncontrolled cancer cell growth. By inhibiting PI3K, Alpesib 150 mg helps to reduce tumor growth and slow disease progression, particularly in patients whose cancer has progressed after initial hormonal therapy.

Clinical Applications:

Alpesib 150 mg is indicated for the treatment of:

• Advanced Breast Cancer: Alpesib 150 mg is used in combination with fulvestrant to treat postmenopausal women, and men with hormone receptor-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. It is effective in managing cancer that has progressed following treatment with endocrine therapy.

Clinical studies have shown that Alpelisib significantly improves progression-free survival in patients with advanced breast cancer, particularly in those with the PIK3CA mutation, making it a critical therapy for this patient group.

Dosage and Administration:

The recommended dosage of Alpesib 150 mg is one tablet taken once daily with food. It is essential for patients to adhere to the prescribed dosage and schedule, as recommended by their healthcare provider. Alpesib 150 mg is typically used in combination with fulvestrant, and patients should undergo regular monitoring for blood sugar levels, as hyperglycemia is a common side effect of the medication.

Benefits of Alpesib 150 mg:

• Targeted Therapy for Breast Cancer: Alpesib 150 mg provides a focused treatment option for patients with advanced breast cancer who have a PIK3CA mutation, helping to control disease progression.
• Proven Efficacy: Clinical studies have demonstrated that Alpesib 150 mg improves progression-free survival in patients with advanced breast cancer, offering hope to patients with limited treatment options.
• Convenient Oral Administration: Alpesib 150 mg is administered orally, making it a convenient treatment option that allows patients to take the medication at home.
• Combination Therapy: When used with fulvestrant, Alpesib 150 mg enhances the effectiveness of the overall treatment strategy, providing a comprehensive approach to managing advanced breast cancer.

Supplier: Orio Pharma

Orio Pharma ensures that Alpesib 150 mg is readily available to healthcare providers and patients, providing reliable access to this essential targeted therapy. Their commitment to efficient supply and distribution supports effective management of advanced breast cancer, improving patient outcomes and quality of life.

Conclusion:

Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd, supplied by Orio Pharma, represents a significant advancement in the treatment of advanced breast cancer. This targeted therapy offers a critical treatment option for patients with PIK3CA-mutated breast cancer, helping to slow disease progression and improve survival outcomes. By incorporating Alpesib 150 mg into their treatment plans, healthcare providers can offer patients a reliable and effective strategy for managing advanced breast cancer, improving their quality of life and health outcomes.